Emcure Pharmaceuticals Q1FY27 Results: Revenue Up 22.8% to ₹25,804 Crore, PAT Rises 36.2%
Emcure Pharmaceuticals reported Q1 FY27 results with revenue at ₹25,804 crore (up 22.8% YoY) and PAT at ₹2,925 crore (up 36.2% YoY). International business grew 34.2%. Mr. Satish Mehta to become Chairman, and Mr. Samit Mehta appointed COO. A conference call is scheduled for August 6, 2026.
The significant increase in revenue and profit, coupled with strategic leadership changes and strong international business performance, is expected to have a material impact on the company's outlook.
The company reported strong year-on-year growth in revenue and profit, along with improved margins. Key leadership appointments also suggest a strategic focus on future growth.
Emcure Pharmaceuticals Limited announced its Unaudited Financial Results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated revenue from operations of ₹25,804 crore, marking a significant year-on-year increase of 22.8%. Profit After Tax (PAT) saw a substantial rise of 36.2% to ₹2,925 crore, with the PAT margin improving by 110 basis points to 11.3%.
The company's performance was driven by strong growth in its international business, which contributed 58% of the total revenue and grew by 34.2% year-on-year, with notable expansion in Europe, Rest of the World (RoW), and Canada. Domestic revenue grew by a resilient 10.2%. EBITDA for the quarter was ₹5,080 crore, up 25.8% year-on-year, with the EBITDA margin improving by 50 basis points to 19.7% due to productivity gains and operating leverage.
Key leadership changes were also announced. Mr. Satish Mehta will take over as Chairman in addition to his existing roles as Managing Director & CEO post the upcoming AGM. Mr. Samit Mehta has been appointed COO of Emcure Pharmaceuticals, gaining broader oversight of the Group’s R&D, operations, and licensing activities, and will also lead Gennova Biopharmaceuticals as its CEO, anchoring the Group's biologics and biosimilars capabilities.
The presentation also highlighted other financial data points, including R&D expenses, capital expenditure, and net debt to TTM EBITDA. Return on Capital Employed (RoCE) stood at 23.4% as of June 30, 2026. The company has scheduled a conference call for August 6, 2026, at 04:00 pm IST to discuss the Q1 FY27 results.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.